Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Directors Deals Ltd.
$12.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lupin Ltd Receives FDA  Approval  For  Its  New  Drug Application For Antara Capsules


Tuesday, 22 Oct 2013 01:41am EDT 

Lupin Ltd announced that it has received final appproval for its supplemental New Drug Application (sNDA) for Antara (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration (FDA). Lupin Pharmaceuticals Inc. (LPI), the Company's US subsidiary would commence marketing the product shortly. LPI currently markets and promotes Antara Capsules, 43 mg & 130 mg strengths. The new drug would be manufactured by Lupin. 

Company Quote

1585.3
30.75 +1.98%
5:13am EST